Letters to the EditorLetter to the Editor
Time for a Relevant Randomized Controlled Trial of Vena Cava Filters
J Osteopath Med; 113(1): 11-12
Abstract
The cost of managing a pulmonary embolism is significant, as is the cost of inserting (and removing) a VCF. Now is the time for a multicenter prospective examination of current optional VCFs. The challenge is to characterize and identify the patient group that will benefit from a VCF, as well as to identify patients who will ultimately benefit from removal of the devices when the PE risk has resolved. Because such a study would be managed in a controlled fashion and clear guidelines would be created for placement and removal, findings could result in a “best practices model” for all.